Gablofen

Abrupt discontinuation may result in high fever, altered mental status, rebound spasticity, muscle rigidity; avoid. Apparent risk patients (eg, spinal cord injury at T-6 or higher, communicative impairment, history of withdrawal symptoms): closely monitor infusion system, dosing schedule, refills, pump alarms, clinical signs of withdrawal or overdose. Avoid use of prefilled syringe in an aseptic setting to fill pumps prior to implantation. Supervise 1^st dose, during titration and refills; have resuscitative equipment and trained personnel available. Do not use chronically if test dose ineffective. For chronic dosing use approved pump (eg, Medtronic SynchroMed II Programmable). Intrathecal mass formation; monitor patients on intraspinal therapy for any new neurological signs or symptoms. Allow at least one year after traumatic brain injury before starting. Intrathecal mass formation; monitor patients on intraspinal therapy for new neurological signs or symptoms; consider consult if symptoms develop. Psychosis. Schizoaffective disorders. Confusion. Autonomic dysreflexia. Infections. Ovarian cysts. Hospitalize immediately if pump malfunction suspected. Pregnancy. Nursing mothers.